Trial Profile
Aprepitant vs. Desloratadine in Non-small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Related Pruritus: A Prospective, Randomized Control, Double-blinded, Phase II Clinical Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Aprepitant (Primary) ; Desloratadine
- Indications Pruritus
- Focus Therapeutic Use
- 05 Oct 2022 Results published in the Cancer
- 19 Jan 2021 Status changed from recruiting to completed.
- 28 Dec 2018 Planned End Date changed from 1 Dec 2017 to 1 Jul 2020.